SAN DIEGO, November 4, 2025 — Leads & Copy — AnaptysBio, Inc. (Nasdaq: ANAB) announced that company leaders will participate in several upcoming investor conferences, including the TD Cowen Immunology & Inflammation Summit (virtual), Guggenheim 2nd Annual Healthcare Innovation Conference (Boston, MA), Stifel 2025 Healthcare Conference (New York, NY), and Jefferies Global Healthcare Conference (London, UK).
Live webcasts and replays will be available on the investor section of Anaptys’ website.
Anaptys is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, completed a Phase 2b trial for rheumatoid arthritis and is in Phase 2 trial for ulcerative colitis. The company’s pipeline includes ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator.
Anaptys has out-licensed multiple therapeutic antibodies, including Jemperli to GSK and imsidolimab to Vanda Pharmaceuticals. The company also announced the intent to separate its biopharma operations from its royalty assets by year-end 2026.
Contact:Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
Source: AnaptysBio, Inc.
